NeurAxis (NRXS): Supplier relationships that shape commercial execution and risk

NeurAxis commercializes neuromodulation devices for chronic conditions and monetizes through device sales and related service contracts, supported by third‑party manufacturing and investor relations channels that facilitate capital market access. Revenue growth is real but small; the company relies on a sole third‑party manufacturer for production and uses short‑term financial advisory services for market access, which together define both upside (scalable commercialization) and outsized operational concentration risk. For investors and operators evaluating NRXS supplier exposure, this note synthesizes every supplier relationship flagged in public reporting and connects contractual constraints to investment implications. Learn more at https://nullexposure.com/.

Quick read: how NeurAxis runs its supply chain and go-to-market

NeurAxis outsources manufacturing of its IB‑STIM device to a single contracted manufacturer in Indiana while retaining product ownership and supplying the necessary equipment. The company supplements commercialization with investor relations and advisory engagements to drive capital markets visibility. That dual model—outsourced manufacturing + outsourced market services—keeps fixed cost low but concentrates execution risk.

Manufacturing is outsourced and critical: filings state NeurAxis does not own a manufacturing facility and relies on one manufacturer; the manufacturer operates under a renew‑able manufacturing services agreement.
Capital markets access is outsourced: NeurAxis uses investor relations and short‑term advisory agreements to support fundraising and investor outreach.
Contract mix is mixed term: the firm has both multi‑year leases/MSAs and one‑year advisory/placement agreements.

If you want a consolidated supplier risk view or to map these relationships into a vendor monitoring program, see https://nullexposure.com/ for structured coverage.

Suppliers and partners investors should track

Masimo — license termination and IP reacquisition

NeurAxis terminated its NSS‑2 Bridge license with Masimo effective July 1, 2025, and regained rights to associated intellectual property for $200,000 payable in two installments, a move that simplifies the company’s IP position and removes ongoing license costs or dependency on Masimo for that asset. This action was reported in press coverage following NeurAxis’s Q2 results. (Source: Globe and Mail press coverage of NRXS Q2 FY2025; corroborated in market write‑ups in mid‑2025.)

Lytham Partners — investor relations and conference participation

NeurAxis engaged Lytham Partners as its investor relations/contact point for shareholder communications and advisory outreach during FY2025, including contact listings in multiple press releases and participation in the Lytham Partners Fall 2025 Investor Conference. The company lists Ben Shamsian of Lytham Partners as its investor relations contact across several disclosures and press announcements. (Source: Globenewswire and Yahoo Finance press releases and investor event notices, FY2025.)

What the contracts and constraints reveal about operating posture

Public filings and press notices together create a clear picture of how NeurAxis structures supplier relationships and what that means for execution.

Contracting posture is mixed but skewed toward renewals. Filings show long‑term real estate commitments (a lease commencing January 1, 2024 with a five‑year initial term) and MSAs with automatic renewal provisions, which indicate a preference for stability in operational contracts. At the same time, advisory and private placement engagements have been one‑year arrangements with explicit monthly fees and warrant compensation, reflecting tactical, short‑term sourcing for capital markets services. (Source: company filings, FY2024–FY2025.)
Framework manufacturing agreement governs serial production. The manufacturing relationship runs as an annual renewable services agreement that the company triggers via purchase orders; the manufacturer uses company‑provided equipment and bears risk for loss and damage. This is a framework procurement posture that supports scale but centralizes production. (Source: company manufacturing services agreement excerpts in filings.)
Concentration and criticality are material. NeurAxis explicitly states it lacks an owned production site and depends on a single third‑party manufacturer in Indiana; the company recognizes that any significant disruption at that supplier would have a material adverse effect. This is a single‑point‑of‑failure risk: production continuity, quality control and contingency capacity are strategic leverage points for investors. (Source: company SEC filings, FY2024–FY2025.)
Geography is local and contained (North America / Indiana). Manufacturing and key facilities are onshore in Indiana, lowering international supply chain complexity but tying operations to local industrial capacity and labor markets. (Source: company filings.)
Supplier maturity and role clarity exist. The manufacturer identified in filings (GMI) has an established footprint and dedicated capacity for IB‑Stim production, and the company classifies the supplier as a manufacturer and active in the manufacturing segment rather than an ad‑hoc contractor. This implies operational maturity at the supplier level even as NeurAxis remains dependent on it. (Source: GMI description in company filings.)

Refer back to https://nullexposure.com/ if you want these constraint signals integrated into a portfolio risk dashboard.

Why these relationships matter for valuation and operations

Revenue leverage is limited but improving: NeurAxis reported revenues in the low millions (Revenue TTM: ~$3.36M) with a gross profit buffer but negative operating margins; stability of supply (and the cost of any alternative sourcing) is central to turning recent revenue growth into sustainable earnings. (Source: company financials, latest reported quarter FY2025.)
IP consolidation reduces third‑party drag: Terminating the Masimo license and reacquiring IP for a defined payment amount removes a legacy dependency and simplifies margin dynamics for products tied to that IP. That action improves optionality around product commercialization and licensing strategy. (Source: Globe and Mail and market reports, FY2025.)
Advisory relationships are tactical capital market levers: Short‑term advisory agreements with defined monthly fees and warrant compensation are designed to amplify fundraising and market visibility rather than to provide long‑term operational services; investors should treat those costs as recurring go‑to‑market spend until capital markets independence is achieved. (Source: company disclosure of advisory agreements, March 2024.)

Practical takeaways for investors and operators

Monitor supplier concentration: a single manufacturer in Indiana is a strategic dependency; verify secondary capacity plans or contractual backup options before increasing position size.
Value IP consolidation: the Masimo license termination simplifies rights and reduces ongoing obligations—adjust forecasts for lower royalty or licensing drag.
Treat advisory spend as ongoing market‑access cost until the company demonstrates independent capital access.

If you want a vendor risk scorecard or ongoing alerts on NRXS supplier developments, visit https://nullexposure.com/ to subscribe to supplier‑level monitoring and company constraint feeds.

Closing action points

For active investors, demand disclosure on contingency manufacturing capacity and any lead times for substituting the current manufacturer. For operators and procurement teams, prioritize contractual language that secures capacity, quality SLAs and rapid transfer provisions in case of supplier disruption. NeurAxis’s model gives it commercial optionality but also a concentrated execution risk profile—deploy capital and operational oversight accordingly.

Explore supplier risk tools and updated relationship mapping at https://nullexposure.com/.

NRXS supplier relationships